Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-24-010967
Filing Date
2024-08-06
Accepted
2024-08-06 09:05:34
Documents
87
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q btai-20240630x10q.htm   iXBRL 10-Q 2436830
2 EX-10.1 btai-20240630xex10d1.htm EX-10.1 30740
3 EX-31.1 btai-20240630xex31d1.htm EX-31.1 17375
4 EX-31.2 btai-20240630xex31d2.htm EX-31.2 17594
5 EX-32.1 btai-20240630xex32d1.htm EX-32.1 10355
6 EX-32.2 btai-20240630xex32d2.htm EX-32.2 8788
7 GRAPHIC btai-20240630x10q006.jpg GRAPHIC 87847
8 GRAPHIC btai-20240630x10q007.jpg GRAPHIC 80261
  Complete submission text file 0001558370-24-010967.txt   9579881

Data Files

Seq Description Document Type Size
9 EX-101.SCH btai-20240630.xsd EX-101.SCH 53672
10 EX-101.CAL btai-20240630_cal.xml EX-101.CAL 45706
11 EX-101.DEF btai-20240630_def.xml EX-101.DEF 264830
12 EX-101.LAB btai-20240630_lab.xml EX-101.LAB 509431
13 EX-101.PRE btai-20240630_pre.xml EX-101.PRE 416721
90 EXTRACTED XBRL INSTANCE DOCUMENT btai-20240630x10q_htm.xml XML 1378135
Mailing Address 555 LONG WHARF DRIVE NEW HAVEN CT 06511
Business Address 555 LONG WHARF DRIVE NEW HAVEN CT 06511 203-643-8060
BioXcel Therapeutics, Inc. (Filer) CIK: 0001720893 (see all company filings)

EIN.: 821386754 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38410 | Film No.: 241177290
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)